Sei Investments Co. lowered its position in Repligen Co. (NASDAQ:RGEN – Free Report) by 15.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 218,714 shares of the biotechnology company’s stock after selling 40,227 shares during the quarter. Sei Investments Co. owned approximately 0.39% of Repligen worth $40,226,000 at the end of the most recent reporting period.
A number of other large investors have also recently added to or reduced their stakes in RGEN. YHB Investment Advisors Inc. acquired a new stake in shares of Repligen during the 1st quarter worth about $26,000. Benjamin F. Edwards & Company Inc. lifted its stake in shares of Repligen by 152.1% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock worth $43,000 after buying an additional 146 shares during the last quarter. Principal Securities Inc. acquired a new stake in shares of Repligen during the 4th quarter worth about $48,000. CWM LLC lifted its stake in shares of Repligen by 19.9% during the 1st quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock worth $66,000 after buying an additional 60 shares during the last quarter. Finally, Signaturefd LLC lifted its stake in shares of Repligen by 48.4% during the 4th quarter. Signaturefd LLC now owns 417 shares of the biotechnology company’s stock worth $75,000 after buying an additional 136 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.
Repligen Price Performance
RGEN stock traded down $3.32 during mid-day trading on Monday, hitting $122.60. The stock had a trading volume of 518,438 shares, compared to its average volume of 594,715. The company has a current ratio of 6.35, a quick ratio of 5.24 and a debt-to-equity ratio of 0.26. Repligen Co. has a 52 week low of $110.45 and a 52 week high of $211.13. The firm has a market capitalization of $6.85 billion, a P/E ratio of 490.70, a P/E/G ratio of 4.21 and a beta of 0.96. The firm has a fifty day simple moving average of $143.06 and a 200 day simple moving average of $169.73.
Insider Activity at Repligen
In related news, CEO Anthony Hunt sold 20,072 shares of Repligen stock in a transaction that occurred on Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the sale, the chief executive officer now directly owns 163,177 shares of the company’s stock, valued at approximately $27,456,162.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Anthony Hunt sold 20,072 shares of Repligen stock in a transaction that occurred on Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the sale, the chief executive officer now directly owns 163,177 shares of the company’s stock, valued at approximately $27,456,162.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Martin D. Madaus purchased 1,615 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The shares were bought at an average cost of $124.94 per share, for a total transaction of $201,778.10. Following the completion of the acquisition, the director now directly owns 4,613 shares in the company, valued at approximately $576,348.22. The disclosure for this purchase can be found here. 1.20% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
RGEN has been the subject of a number of research reports. Guggenheim initiated coverage on shares of Repligen in a research note on Tuesday, June 18th. They set a “neutral” rating for the company. Deutsche Bank Aktiengesellschaft upgraded shares of Repligen from a “hold” rating to a “buy” rating and dropped their price objective for the stock from $180.00 to $155.00 in a research note on Wednesday, June 26th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, May 2nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $193.00.
Check Out Our Latest Stock Analysis on Repligen
Repligen Company Profile
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Read More
- Five stocks we like better than Repligen
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Automaker’s Bold Move to an EV Future: Is It Time to Buy Stock?
- How to invest in marijuana stocks in 7 stepsĀ
- Massive Breakout: This ETF Signals Big Gains for Small-Cap Stocks
- Stock Average Calculator
- Major Gaming Stock to Watch: Why It’s a Safe Bet Now
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN – Free Report).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.